Maintenance Capecitabine Dosing and Duration
For maintenance therapy in colorectal cancer, capecitabine should be dosed at 1000-1250 mg/m² orally twice daily for 14 days followed by a 7-day rest period, repeated every 3 weeks, and continued until disease progression or unacceptable toxicity. 1
Standard Dosing Regimen
The FDA-approved dosing for capecitabine (Xeloda) is 1250 mg/m² twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles 1. However, for maintenance therapy specifically:
- Dose: 1000-1250 mg/m² orally twice daily on days 1-14
- Cycle: Every 21 days (14 days on, 7 days off)
- Duration: Continue until disease progression or unacceptable toxicity
Important Geographic Consideration
North American patients typically require lower starting doses (1000 mg/m²) compared to European patients (1250 mg/m²) due to greater toxicity with fluoropyrimidines 2, 3, 4. Start at 1000 mg/m² twice daily with close monitoring during the first cycle, then adjust as tolerated.
Duration of Therapy
For Metastatic Disease (Maintenance Setting)
Continue indefinitely until disease progression or unacceptable toxicity 1. The evidence supports:
- In metastatic colorectal cancer after response to combination therapy: median time to progression of 4.4 months with maintenance capecitabine 5
- In metastatic nasopharyngeal carcinoma: capecitabine maintenance (1000 mg/m² twice daily days 1-14 every 3 weeks) significantly improved PFS to 35.9 months versus 8.2 months with best supportive care alone 6
For Adjuvant Colon Cancer
Total duration of 6 months (8 cycles of 3 weeks = 24 weeks) for Dukes' C colon cancer 1. This is the only setting with a defined endpoint rather than treatment until progression.
Alternative Maintenance Schedules
For patients developing hand-foot syndrome or requiring chronic low-dose maintenance:
1000 mg twice daily, 5 days on/2 days off continuously (without the traditional 1-week break) has shown acceptable safety in gastrointestinal cancers 7. This schedule demonstrated:
- Only grade 1-2 toxicities (primarily fatigue and hand-foot syndrome)
- Single grade 3 event, no grade 4 toxicities
- Suitable for long-term chronic administration
Dose Modifications for Toxicity
Once dose is reduced, it should NOT be increased later 1. For grade 2-3 toxicities:
- Grade 2 during treatment: Interrupt until resolved to grade 0-1, may resume at same dose during cycle
- Grade 3 during treatment: Interrupt until resolved to grade 0-1, resume at 75% of original dose
- Grade 4: Discontinue permanently
Renal Impairment Adjustments
- Moderate impairment (CrCl 30-50 mL/min): Reduce starting dose to 75% (approximately 950 mg/m² twice daily)
- Severe impairment (CrCl <30 mL/min): Contraindicated
Context-Specific Recommendations
Triple-Negative Breast Cancer
Low-dose maintenance at 650 mg/m² twice daily continuously for 1 year after standard adjuvant chemotherapy significantly improved 5-year disease-free survival (82.8% vs 73.0%, HR 0.64, p=0.03) 8. This lower continuous dosing differs from the standard intermittent schedule.
Combination with Other Agents
When combined with docetaxel or other agents during active treatment, use 1250 mg/m² (or 950 mg/m² for docetaxel combinations in some protocols) twice daily days 1-14 every 3 weeks 9. After achieving disease control, transition to single-agent maintenance at the doses above.
Critical Safety Monitoring
The most common dose-limiting toxicity is hand-foot syndrome (45.2% any grade, 7.7% grade 3) 8. Monitor closely during first cycle and adjust dose preemptively if grade 2 toxicity develops. Other significant toxicities include anemia (12%), nausea/vomiting (6%), and fatigue (4%) during maintenance 6.
Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe, life-threatening toxicity and should not receive capecitabine 10.